List of Excipients in Branded Drug PREVACID

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC	PREVACID	lansoprazole	0067-6286	D&C RED NO. 28
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC	PREVACID	lansoprazole	0067-6286	FD&C BLUE NO. 1
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC	PREVACID	lansoprazole	0067-6286	FD&C GREEN NO. 3
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC	PREVACID	lansoprazole	0067-6286	FD&C RED NO. 40

Last updated: August 9, 2026

ecutive summary: Prevacid is the lansoprazole brand, a mature proton-pump inhibitor with extensive generic competition. Its main commercial value no longer lies in the active ingredient patent. Opportunities are concentrated in excipient-enabled differentiation: stable enteric-coated multiparticulates, orally disintegrating tablets, pediatric liquids, sprinkle formulations, taste masking, lower-cost coating systems, and improved moisture protection. Because lansoprazole is acid-labile, the central formulation requirement is separation of the drug from gastric acid through an enteric barrier. New products must establish meaningful clinical, usability, manufacturing, or regulatory differentiation rather than rely on routine excipient substitution.

Prevacid Lansoprazole Excipient Strategy and Commercial Opportunities

What is Prevacid and which formulations use lansoprazole?

Prevacid contains lansoprazole, a substituted benzimidazole proton-pump inhibitor. It suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase enzyme system. U.S. prescription formulations have included delayed-release capsules, orally disintegrating tablets, and delayed-release oral suspension products.[1]

Product type	Typical strength	Delivery format	Core formulation issue
Delayed-release capsule	15 mg, 30 mg	Enteric-coated multiparticulate granules in capsule shell	Protect lansoprazole from gastric acid and moisture
Orally disintegrating tablet	15 mg, 30 mg	Granules dispersed in the mouth and swallowed	Rapid disintegration, taste control, acid protection
Delayed-release oral suspension	15 mg, 30 mg packets	Granules mixed with water before administration	Dose uniformity, suspension stability, pediatric usability
OTC delayed-release capsule	Commonly 15 mg	Capsule with enteric-coated pellets	Low-cost mass-market manufacture and shelf stability

The FDA-approved prescription label identifies excipients used in Prevacid formulations, including sucrose or sugar spheres, hypromellose, low-substituted hydroxypropyl cellulose, polyethylene glycol, talc, titanium dioxide, methacrylic acid copolymer, and polysorbate 80 in delayed-release granules. The orally disintegrating tablet also uses excipients such as mannitol, crospovidone, magnesium carbonate, citric acid, aspartame, flavoring agents, and low-substituted hydroxypropyl cellulose.[1]

What excipients protect lansoprazole from gastric acid?

The most important excipient function is enteric protection. Lansoprazole is acid-labile and must remain substantially intact until the dosage form reaches the small intestine.

Enteric polymers

Commercial and generic lansoprazole products commonly use methacrylic acid copolymers or comparable enteric polymers. These polymers remain relatively insoluble under gastric conditions and dissolve at higher intestinal pH.

The formulation can use:

• Methacrylic acid-ethyl acrylate copolymers
• Methacrylic acid-methyl methacrylate copolymers
• Cellulose acetate phthalate or related legacy systems
• Polyvinyl acetate phthalate
• Hydroxypropyl methylcellulose phthalate
• Other pharmacopeial enteric coating materials

The commercial objective is not simply to select an enteric polymer. The developer must control coating weight, film integrity, curing conditions, plasticizer level, and interactions with the drug-containing core.

Alkaline stabilizers

An alkaline microenvironment can improve lansoprazole stability during processing and storage. Potential stabilizing excipients include:

• Magnesium carbonate
• Sodium bicarbonate
• Magnesium oxide
• Calcium carbonate
• Other pharmaceutically acceptable alkaline buffers

The excipient must be compatible with the granule, coating, capsule, suspension, and dissolution profile. Excess alkalinity can affect taste, tablet performance, coating behavior, and dose uniformity.

Seal coats and subcoats

A seal coat can separate the drug-containing core from the enteric film. It may reduce migration of moisture, alkaline materials, pigments, and surfactants into the active layer.

A multilayer structure can include:

1. Inert starter pellet or compressible carrier
2. Drug-containing layer
3. Seal coat
4. Enteric polymer layer
5. Optional overcoat for handling and moisture resistance

This architecture is commercially relevant because a competitor may obtain differentiation through process control and performance, even when it uses conventional excipients.

What excipients are used in Prevacid orally disintegrating tablets?

Prevacid SoluTab was designed to disintegrate on the tongue while preserving delayed release. Its formulation combines rapidly dispersible tablet excipients with acid-protected granules.

Functional role	Relevant excipient classes
Bulking and mouthfeel	Mannitol, sugars, polyols
Disintegration	Crospovidone, low-substituted hydroxypropyl cellulose
Alkaline stabilization	Magnesium carbonate or comparable alkaline materials
Granule protection	Hypromellose and enteric methacrylic acid copolymers
Lubrication and flow	Talc and other processing aids
Taste control	Flavors, sweeteners, polymer coatings
Tablet structure	Direct-compression fillers and binders

The key design constraint is that rapid oral disintegration must not cause premature release of unprotected lansoprazole. The tablet therefore contains delayed-release granules rather than relying on the tablet matrix alone for gastric protection.

Commercial opportunities include:

• Faster tablet dispersion
• Lower residual grittiness
• Reduced coating fracture during compression
• Improved flavor stability
• Reduced sensitivity to humidity
• Alternative sweetener systems for pediatric or diabetic populations
• Aspartame-free formulations
• Smaller tablets at equivalent dose
• Better compatibility with water or soft food administration

The use of aspartame in a formulation can create a market opportunity for an alternative product directed to patients with phenylketonuria or consumers seeking an aspartame-free product. Any such product would still require acceptable taste, stability, and bioequivalence performance.

What excipients are used in lansoprazole oral suspension products?

Delayed-release oral suspension products use lansoprazole granules that are mixed with water before administration. Sodium bicarbonate and other suspension or flavoring excipients may support stabilization and palatability, depending on the specific product and approved label.[1,2]

A commercial suspension strategy must solve four problems:

1. The granules must remain physically dispersed long enough for administration.
2. The active ingredient must remain protected from gastric acid.
3. The final dose must be uniform across the preparation period.
4. The product must be acceptable to children and patients with swallowing difficulty.

Potential excipient opportunities include:

• Xanthan gum or comparable suspending agents
• Low-viscosity cellulose derivatives
• pH-adjusting buffers
• Sugar-free sweetener systems
• Fruit or neutral flavor systems
• Preservative systems for multidose presentations
• Single-dose powder packets that eliminate preservative requirements

A single-dose packet may have a higher packaging cost but reduce microbial risk, dosing errors, and caregiver handling. A multidose liquid may offer greater convenience but introduces preservative, in-use stability, and measuring-device requirements.

What patent protection covers Prevacid and lansoprazole formulations?

The original lansoprazole compound and early pharmaceutical composition patents are expired in the United States. The foundational lansoprazole patent family dates to the 1980s and did not provide a current barrier to generic entry. FDA-approved generic lansoprazole products have been marketed for years under the ANDA pathway.[3,4]

Protection category	Current commercial relevance
Original lansoprazole compound patent	Expired
Early delayed-release composition patents	Historical protection; generally expired
Brand capsule formulation	No practical barrier to ordinary generic competition
Orally disintegrating tablet technology	Potentially relevant only if a live, claim-specific patent remains
Pediatric suspension formulation	May support formulation differentiation, but must be checked against current patent records
Manufacturing process patents	Potential value if claims cover a non-obvious, scalable process
Excipient-specific claims	Strong only when tied to defined performance and non-routine formulation relationships

A routine substitution of one filler, disintegrant, flavor, or enteric polymer generally provides weak patent value. Stronger protection is more likely where the claims connect excipient composition to measurable outcomes, such as:

• Defined dissolution under gastric and intestinal conditions
• Long-term stability at elevated humidity
• Reduced degradation products
• Controlled pellet size distribution
• Improved dose uniformity
• Reduced coating defects
• Improved taste without compromising acid resistance
• A specific reconstitution or administration profile

Patent term, claim scope, Orange Book listing status, and litigation history must be checked for each proposed product. A formulation patent may not be Orange Book-listed if it does not claim an approved method of use or drug product in a manner eligible for listing.

What is the Orange Book status of Prevacid?

The FDA Orange Book is the controlling source for current listed patents, therapeutic equivalence codes, and approval records.[3] Prevacid and generic lansoprazole products are small-molecule products, not biologics. Their market-entry framework is therefore ANDA-based, not biosimilar-based.

Generic applicants may file:

• Paragraph I certification when no patent is listed
• Paragraph II certification when a listed patent has expired
• Paragraph III certification accepting delayed approval until patent expiration
• Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed

For a mature product such as lansoprazole, Paragraph II and Paragraph III filings are generally more commercially relevant than a new Paragraph IV campaign unless an unexpired formulation or method patent remains listed.

Which companies are challenging Prevacid exclusivity?

Generic competition has already displaced most originator exclusivity for lansoprazole. The relevant competitive group includes manufacturers of generic delayed-release capsules, orally disintegrating tablets, and suspension products. Public FDA approval records, the Orange Book, ANDA labels, and court dockets are the principal sources for identifying current applicants and litigation.

No biosimilar challenge applies because lansoprazole is a chemically synthesized small molecule. The relevant threats are:

• Generic capsule entry
• Generic orally disintegrating tablet entry
• Authorized-generic pricing
• OTC private-label competition
• Formulation substitution
• Pharmacy and wholesaler purchasing pressure

A company developing a new lansoprazole product should expect limited protection from the active ingredient and should assess whether the proposed excipient system creates a genuine product-level advantage.

When does Prevacid lose exclusivity?

Prevacid lost meaningful U.S. market exclusivity years ago. The original compound and early formulation protection expired before the current generic market matured. Pediatric exclusivity and other regulatory extensions associated with the historical product lifecycle did not create a durable commercial barrier.

The practical exclusivity timeline is:

Milestone	Commercial effect
Original FDA approval in the 1990s	Established the prescription brand
Expiration of foundational compound protection	Opened the market to generic lansoprazole
Generic ANDA approvals	Created price competition across dosage forms
OTC commercialization	Expanded consumer access and intensified retail competition
Current market	Differentiation depends on formulation, access, price, and channel execution

What generic launch risks exist for new lansoprazole products?

A new generic or reformulated product faces several risks.

Regulatory risk

The applicant must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. For delayed-release products, dissolution testing is central. For orally disintegrating tablets and suspensions, the applicant must also control dosage-form performance and administration conditions.[5]

Manufacturing risk

Multiparticulate products require consistent control of:

• Pellet or granule size
• Drug-layer uniformity
• Enteric coating thickness
• Coating curing
• Residual solvent or moisture
• Capsule fill weight
• Dissolution after storage
• Mechanical damage during packaging

Commercial risk

The market is price-sensitive and has multiple established suppliers. A formulation with higher excipient or packaging cost must generate a clear advantage, such as a pediatric indication, pharmacy preference, better adherence, or a differentiated retail position.

IP risk

The main risk is usually not the expired lansoprazole compound patent. It is the possibility of a live formulation, process, use, or device patent connected to a particular product configuration. A freedom-to-operate review should distinguish between:

• Patents that cover the active ingredient
• Patents that cover a specific formulation
• Patents that cover a method of administration
• Patents that cover manufacturing equipment or process parameters
• Patents that are listed in the Orange Book
• Patents that are enforceable but not Orange Book-listed

How strong is the Prevacid patent estate?

The legacy Prevacid patent estate is weak as a barrier to ordinary generic lansoprazole capsules. The active ingredient is mature, generic products are established, and common excipients do not usually create durable exclusivity.

A new formulation patent estate could be stronger if it includes:

• Multiple independent claims covering the composition and manufacturing process
• Defined excipient ratios
• Stability data tied to the claimed composition
• Dissolution performance across relevant pH conditions
• Claims covering pediatric or geriatric administration
• Claims that distinguish the product from marketed generics
• Manufacturing controls that are difficult to design around

Patent strength should be evaluated by claim breadth, prior-art exposure, enablement, written description, detectability, and design-around cost. A patent that claims only a conventional enteric polymer at an ordinary concentration is likely to have limited strategic value.

What licensing deals and commercial partnerships are relevant?

The principal commercial opportunity is unlikely to be a license to the expired lansoprazole molecule. Licensing value is more likely to arise from:

• Proprietary enteric coating technology
• Taste-masking technology
• Pediatric multiparticulate delivery
• Low-moisture packaging
• Unit-dose suspension systems
• Contract manufacturing capacity
• OTC brand or private-label distribution rights

A technology owner could license an excipient platform to a generic manufacturer, consumer-health company, or specialty pharmaceutical company. The strongest deal structure would tie royalties to a differentiated product with defined regulatory and commercial advantages rather than to routine lansoprazole supply.

Public FDA and Orange Book records do not establish a current exclusive U.S. license that blocks generic commercialization of lansoprazole. Commercial rights for particular Prevacid branded or OTC products can differ by jurisdiction and channel.

How does Prevacid compare with competing proton-pump inhibitors?

Lansoprazole competes with omeprazole, esomeprazole, pantoprazole, and rabeprazole. All are mature proton-pump inhibitors with substantial generic competition.

Product	Active ingredient	Typical formulation opportunity
Prevacid	Lansoprazole	Enteric pellets, ODT, pediatric suspension, taste masking
Prilosec	Omeprazole	Delayed-release pellets, OTC capsules, combination products
Nexium	Esomeprazole	Delayed-release capsules, granules, suspension, branded differentiation
Protonix	Pantoprazole	Delayed-release tablets, hospital and prescription channels
AcipHex	Rabeprazole	Delayed-release tablets, alternative release and stability profiles

Lansoprazole has a relatively attractive excipient-development profile because its product history includes multiple dosage forms. The main opportunities are usability and manufacturing economics, not molecule-level exclusivity.

What are the best commercial opportunities for lansoprazole excipients?

The highest-probability opportunities are:

1. Pediatric and swallowing-friendly products using stable granules, improved flavor, and single-dose packaging.
2. Aspartame-free orally disintegrating tablets.
3. Lower-cost enteric coating systems with equivalent dissolution and stability.
4. Moisture-resistant packaging for hot and humid markets.
5. Sugar-free or reduced-sugar formulations for consumer-health channels.
6. Improved multiparticulate products that can be administered with soft food.
7. Unit-dose suspension products with simplified reconstitution.
8. Manufacturing platforms that reduce coating time, rejects, or solvent use.

Geographic opportunities are strongest in markets where prescription PPIs remain widely used, pediatric liquid products are underdeveloped, and temperature or humidity creates stability problems. Regional regulatory requirements for excipient acceptability, labeling, preservatives, and bioequivalence must be assessed separately.

Key Takeaways

• Prevacid is a mature lansoprazole product with expired foundational molecule protection.
• The key formulation challenge is protecting acid-labile lansoprazole until intestinal release.
• Enteric polymers, alkaline stabilizers, seal coats, disintegrants, and taste-masking systems drive product performance.
• The strongest commercial opportunities are pediatric, orally disintegrating, suspension, sprinkle, sugar-free, and moisture-resistant products.
• Routine excipient substitutions have limited patent value.
• Defensible IP should connect defined excipient systems to measurable stability, dissolution, taste, or manufacturing benefits.
• Lansoprazole is a small molecule, so biosimilar risk does not apply.
• Generic competition and price pressure make manufacturing cost, pharmacy acceptance, and patient usability central to launch economics.
• The FDA Orange Book and current product labels control the assessment of patent listings and regulatory status.

FAQs

Can lansoprazole be formulated without an enteric coating?

A conventional immediate-release lansoprazole product would face acid degradation and would require a different stabilization and delivery strategy. Enteric protection remains the standard approach for delayed-release oral products.

Is magnesium carbonate a patentable excipient strategy for Prevacid?

Magnesium carbonate alone is unlikely to provide strong protection because alkaline stabilizers are known formulation tools. Patent value would depend on a defined composition, performance advantage, and non-obvious relationship between the excipient and product attributes.

Are Prevacid orally disintegrating tablets interchangeable with capsules?

Therapeutic equivalence depends on the specific FDA-approved product and its Orange Book code. Dosage form, strength, release characteristics, and labeling must be evaluated rather than assumed to be interchangeable.

What packaging provides the best protection for lansoprazole?

High-barrier blister packaging, desiccant-supported bottles, and unit-dose foil systems can reduce moisture exposure. The best choice depends on stability data, manufacturing cost, dosing frequency, and distribution conditions.

Can a new lansoprazole liquid qualify for a 505(b)(2) application?

A 505(b)(2) pathway may be relevant to a product that relies partly on existing findings but introduces a meaningful change in formulation, dosage form, route, or labeling. The regulatory classification depends on the specific product and FDA requirements.

References

1. Takeda Pharmaceuticals U.S.A., Inc. (2012). Prevacid and Prevacid SoluTab prescribing information. U.S. Food and Drug Administration.

2. National Library of Medicine. (n.d.). DailyMed: Lansoprazole delayed-release oral suspension and delayed-release capsule labeling. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2000). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/waiver-vivo-bioavailability-and-bioequivalence-studies-immediate-release-solid-oral-dosage-forms